{"id":"NCT01808573","sponsor":"Puma Biotechnology, Inc.","briefTitle":"A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting","officialTitle":"A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-29","primaryCompletion":"2018-09-28","completion":"2019-12-09","firstPosted":"2013-03-11","resultsPosted":"2019-12-11","lastUpdate":"2021-06-11"},"enrollment":621,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HER2+ Metastatic Breast Cancer (MBC)"],"interventions":[{"type":"DRUG","name":"neratinib","otherNames":["Nerlynx"]},{"type":"DRUG","name":"capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"lapatinib","otherNames":["Tykerb","Tyverb"]}],"arms":[{"label":"neratinib plus capecitabine","type":"EXPERIMENTAL"},{"label":"lapatinib plus capecitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.","primaryOutcome":{"measure":"Centrally Assessed Progression Free Survival","timeFrame":"From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.","effectByArm":[{"arm":"Neratinib Plus Capecitabine","deltaMin":8.8,"sd":null},{"arm":"Lapatinib Plus Capecitabine","deltaMin":6.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0059"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":252,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Hong Kong","Ireland","Israel","Italy","Japan","Netherlands","Portugal","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34553296","32678716"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":103,"n":303},"commonTop":["Diarrhoea","Palmar-plantar erythrodysaesthesia syndrome","Nausea","Vomiting","Fatigue"]}}